{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-assessment/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"07b5f362-627f-5d8a-8d01-b917142582c2","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 99fc9f03-0ba3-4def-ba54-abeccfea1088 --><h2>Changes</h2><!-- end field 99fc9f03-0ba3-4def-ba54-abeccfea1088 -->","summary":null,"htmlStringContent":"<!-- begin item 2d042724-085f-4a69-9e9a-6efd5c52b278 --><!-- begin field 61191cb3-a31e-4ef6-a1c4-63e476e41bb4 --><p><strong>September 2019</strong> — minor update. Updated to clarify that the ethical and legal issues that need to be considered when assessing suitability for contraception apply to women with learning disabilities, not people with learning difficulties.</p><p><strong>May 2019</strong> — minor update. Topic updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) guidelines <em>Overweight, Obesity and Contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2019</a>].</p><p><strong>December 2017</strong> — minor update. Added information about fetal malformations and effectiveness of hormonal contraceptives as an effect of topiramate.</p><p><strong>August to September 2016</strong> — reviewed. A literature search was conducted in August 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor structural changes have been made.</p><!-- end field 61191cb3-a31e-4ef6-a1c4-63e476e41bb4 --><!-- end item 2d042724-085f-4a69-9e9a-6efd5c52b278 -->","topic":{"id":"b3143012-a228-55f5-8507-b5b650690e4c","topicId":"32f1df2c-afc0-4f35-be88-49caf8770b41","topicName":"Contraception - assessment","slug":"contraception-assessment","lastRevised":"Last revised in September 2019","chapters":[{"id":"8d7c8a25-4e93-5a42-928f-f6611bb74f8b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f6467a38-cb74-5956-9113-c5ea6b3e26b3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6121a83b-02e9-52ac-a8f9-0998004484bc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"07b5f362-627f-5d8a-8d01-b917142582c2","slug":"changes","fullItemName":"Changes"},{"id":"0df9a885-e331-5bb2-aa56-e9c271c953dc","slug":"update","fullItemName":"Update"}]},{"id":"699be09a-1785-5ab5-bf3b-cf106ce69b83","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59c7a2c-4736-5055-b01b-29e6039bc23b","slug":"goals","fullItemName":"Goals"},{"id":"8e96e0e4-38c0-5981-bfd3-d340e227337e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df0725fd-cf61-5019-a02b-7c6e05ca6d55","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"86b18852-547f-5859-960f-b4512c2736c1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"61cea463-ab64-5105-8179-666b624b775b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8d52411f-5b91-53ff-87d9-703de7ff4ff1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6a02d9d-3223-585d-89bb-915cc73d1565","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6218ca2-8f9c-534f-95be-c1a373a78494","slug":"comparative-effectiveness-of-contraceptive-methods","fullItemName":"Comparative effectiveness of contraceptive methods"},{"id":"1e7241c0-cd2e-5c44-a7d0-01f505a5f6df","slug":"available-contraceptive-methods-in-the-uk","fullItemName":"Available contraceptive methods in the UK"}]},{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"de31dc4a-7073-5d0b-83fb-9e0af6e49a7b","slug":"issues-to-consider-discuss","fullItemName":"Scenario: Issues to consider and discuss"},{"id":"10acf1be-13df-5c89-8f9c-6c905784040b","slug":"comorbidities-special-situations","fullItemName":"Scenario: Comorbidities and special situations"},{"id":"04a5ef68-fad9-5897-8a64-10294e5004a2","slug":"prescribing-to-young-people","fullItemName":"Scenario: Prescribing to young people"},{"id":"012d4729-63d2-51ca-a18c-bbd593b74fa4","slug":"approaching-the-menopause","fullItemName":"Scenario: Approaching the menopause"},{"id":"5970d6e3-da30-5c77-b143-090babc6df1b","slug":"assessment-for-specific-contraceptive-methods","fullItemName":"Scenario: Assessment for specific contraceptive methods"}]},{"id":"1f285502-649a-5805-a56d-1819aafe2ef0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2c624d48-ad5c-53e5-afd7-03cbcb0af45d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"040eb257-bbbd-5695-8eda-cde5a6b0991e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"582f4ca4-299f-54d7-ac03-285acee6a6d6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c6171063-570c-5710-a837-052779620da6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"278eb9ce-8d46-577d-bc1b-19866cb57433","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7e6a7d96-a9eb-5bb8-bb74-9a82eb3efeaa","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"83baf2bb-d418-5417-9e87-94f055e1ea8a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6121a83b-02e9-52ac-a8f9-0998004484bc","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f899c42c-38a8-5ecf-a2b9-1f72545a7d78","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 9a353fbd-51f5-403d-812a-46d75d2fcf81 --><h3>Previous changes</h3><!-- end field 9a353fbd-51f5-403d-812a-46d75d2fcf81 -->","summary":null,"htmlStringContent":"<!-- begin item c72d59cd-3dd9-4ded-b05d-ae574a28ec30 --><!-- begin field 50ec8dc5-c515-481c-99d6-b61c5ca0ff50 --><p><strong>July 2014</strong> — minor update. Update to the 'Have I got the right topic section?' to state that this CKS topic does not cover the management or contraceptive choice in women who have cardiovascular disease. Links have been inserted within the topic to the new Faculty of Sexual and Reproductive Health guidance on women who have cardiovascular disease.</p><p><strong>August 2013</strong> — minor update. Added a text to clarify that when used for the purpose of oestrogen replacement therapy the levonorgestrel intrauterine system (LNG-IUS) should be retained for no longer than 5 years after insertion (the licence states 4 years), regardless of the age of the woman at insertion.</p><p><strong>June 2013</strong> — minor update. The 2013 Quality and Outcomes Framework (QOF) options for local implementation have been added to this topic.</p><p><strong>May 2013</strong> — minor update. Linking error corrected in the Epilepsy node in Scenario: Comorbidities and special situations.</p><p><strong>March 2013</strong> — minor update. The telephone number for NHS Direct has been updated.</p><p><strong>February to June 2012</strong> — reviewed. A literature search was conducted in December 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made. However, recommendations have been rewritten for clarity, and superseded guidelines and manufacturers' Summary of Product Characteristics have been updated accordingly.</p><p><strong>January 2012</strong> — mirror error corrected. Clarified the UK medical eligibility criteria for the use of progestogen-only pills in women with a past history (5 years or more) of migraine with aura, at any age.</p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. Issued in June 2011.</p><p><strong>February 2011</strong> — minor update. The Faculty of Sexual and Reproductive Healthcare (FSRH) no longer recommends that additional contraception is required during or after courses of antibiotics that do not induce liver enzymes. However, additional contraceptive precautions are required if the antibiotic or illness causes vomiting or diarrhoea. </p><p><strong>August 2010</strong> — updated. The section on contraceptive choices in women approaching the menopause has been updated to include the FSRH guidance on <em>Contraception in women aged over 40 years.</em></p><p><strong>June 2010</strong> — updated. The section on contraceptive choices in young women under 18 years of age has been updated in line with the FSRH guidance <em>Contraceptive choices for young people</em>. A prescription for Levest®, a new ethinylestradiol plus levonorgestrel combined oral contraceptive pill, has been added. </p><p><strong>March 2010</strong> — minor update. The section on prescribing for women with epilepsy has been updated in line with the FSRH statement on antiepileptic drugs and contraception.</p><p><strong>February 2010</strong> — updated to include the revised <em>UK medical eligibility criteria for contraceptive use</em>, as published by the FRSH, formerly the Faculty of Family Planning and Reproductive Healthcare (FFPRHC).</p><p><strong>October 2009</strong> — minor update. The advice about when to a remove a copper intrauterine device (Cu-IUD) or a levonorgestrel intrauterine system (LNG-IUS) in a woman with pelvic inflammatory disease has also been updated. </p><p><strong>March 2009</strong> — minor update. The QOF indicators for sexual health have been updated in the Goals and outcome measures section.</p><p><strong>September 2008</strong> — minor correction. Typographical and table heading corrections to UK medical eligibility criteria tables on Cu-IUD and the LNG-IUS. </p><p><strong>April to September 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>September 2004</strong> — updated to include the WHO Medical Eligibilty Criteria relating to contraception for 2004. </p><p><strong>January 2004</strong> — reviewed. Validated in March 2004 and issued in June 2004.</p><p><strong>January 2001</strong> — rewritten. Validated in March 2001 and issued in June 2001. Guidance on emergency contraception is no longer included in the Contraception guidance but can be found as a separate CKS topic.</p><p><strong>December 1997</strong> — written.</p><!-- end field 50ec8dc5-c515-481c-99d6-b61c5ca0ff50 --><!-- end item c72d59cd-3dd9-4ded-b05d-ae574a28ec30 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}